ALNY ALNYLAM PHARMACEUTICALS, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$272.67

Period return

-92.79 (-25.39%)

Volume

1.4M

2026-07-20O $267.55 H $275.25 L $266.27 C $272.67MA5 $276.74MA20 $295.18MA60 $295.37MA120 $310.44

6M · 124 barsYahoo Finance · USD2026-01-21 → 2026-07-20

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 30.Highin 9 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 19.MediumBUY2 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.56%
2026. 05. 05.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 02.LowBUY3 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 05. 01.LowHOLD3 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 04. 14.LowBUY3 months ago
Truist Securities: Buy
US analyst rating / recommendation change.
2026. 03. 26.LowBUY4 months ago
Chardan Capital: Buy
US analyst rating / recommendation change.
2026. 03. 26.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 16.MediumHOLD4 months ago
Jefferies: Hold
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $445.81 · 27 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 30.	After market close (AMC)	$2.17	—	—	$1.32B	—	Scheduled
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-1.53	—	—	$1.66B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.66	—	—	$1.15B	Reported
FY2025 Q1	2024. 03. 31.	Time TBD	—	$-0.52	—	—	$494.33M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,992,577	$659.28M	0.56%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	616,120	$245M	0.38%	—	New position

ALNYLAM PHARMACEUTICALS, INC.알닐람

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 19.	Citigroup	—	Initiate coverage	— → Buy	—	Citigroup: Buy
2026. 05. 05.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 02.	RBC Capital	—	Maintain	Outperform → Outperform	—	RBC Capital: Outperform
2026. 05. 01.	Wells Fargo	—	Maintain	Equal-Weight → Equal-Weight	—	Wells Fargo: Equal-Weight
2026. 04. 14.	Truist Securities	—	Maintain	Buy → Buy	—	Truist Securities: Buy
2026. 03. 26.	Chardan Capital	—	Maintain	Buy → Buy	—	Chardan Capital: Buy